Nasseri Y, Cassella L, Berns M, Zaghiyan K, Cohen J
The Surgery Group of Los Angeles, Los Angeles, California, USA.
Division of Colon and Rectal Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Colorectal Dis. 2016 Apr;18(4):351-6. doi: 10.1111/codi.13268.
This study aimed to review, consolidate and analyse the findings of studies investigating the efficacy of anal fistula plugs (AFPs) in treating fistula-in-ano in patients with Crohn's disease.
A literature review was conducted via Pubmed, Embase, Medline, Scopus and the Cochrane Library for the period 1995-2015. Articles were selected and reviewed based on specific inclusion and exclusion criteria.
A total of 16 studies were extracted, of which 12 were included in the systematic review. In total, 84 patients (n = 1-20 per study) with a median age of 45 (18-72) years and a median follow-up time of 9 (3-24) months were analysed. The total success rate, defined as closure of the fistula tract, was 49/84 (58.3%, 95% CI 47-69). Success in patients with recurrent anal fistulae was 2/5 (40%, 95% CI 5-85). Overall, the success rates of Surgisis and GORE BIO-A brand plugs were 48/80 (60%, 95% CI 48-71) and 1/4 (25%, 95% CI 1-81). The recurrence rate of fistula-in-ano in the five studies that reported recurrence was 3/22 (13.6%). In two comparative studies, inferior overall success rates were found in patients who received preoperative immunomodulators vs. those who did not [3/11 (27.3%) vs. 17/23 (73.9%)].
The studies suggest that the use of an AFP in patients with Crohn's disease is a safe procedure with reasonable success, little morbidity and a low risk of incontinence. The current literature is limited by a number of factors, including small study cohorts, grouping of fistulae in Crohn's disease with other types of anal fistula, short and highly variable follow-up times and multiple confounding factors such as number of fistula tracts, use of preoperative steroids or immunosuppressants, previous use of setons and variation in surgical technique.
本研究旨在回顾、整合并分析有关肛瘘塞(AFP)治疗克罗恩病患者肛瘘疗效的研究结果。
通过PubMed、Embase、Medline、Scopus和Cochrane图书馆对1995年至2015年期间的文献进行综述。根据特定的纳入和排除标准选择并审查文章。
共提取了16项研究,其中12项纳入系统评价。总共分析了84例患者(每项研究1 - 20例),中位年龄45岁(18 - 72岁),中位随访时间9个月(3 - 24个月)。定义为瘘管闭合的总成功率为49/84(58.3%,95%可信区间47 - 69)。复发性肛瘘患者的成功率为2/5(40%,95%可信区间5 - 85)。总体而言,Surgisis和GORE BIO - A品牌塞的成功率分别为48/80(60%,95%可信区间48 - 71)和1/4(25%,95%可信区间1 - 81)。在报告复发情况的五项研究中,肛瘘的复发率为3/22(13.6%)。在两项比较研究中,接受术前免疫调节剂治疗的患者总体成功率低于未接受者[3/11(27.3%)对17/23(73.9%)]。
研究表明,在克罗恩病患者中使用AFP是一种安全的手术方法,成功率合理,发病率低,失禁风险低。目前的文献受到多种因素的限制,包括研究队列小、将克罗恩病肛瘘与其他类型肛瘘分组、随访时间短且高度可变以及多个混杂因素,如瘘管数量、术前使用类固醇或免疫抑制剂、既往使用挂线以及手术技术差异。